Список трудов авторов, использованных при подготовке статей по лечению гормонами раннего рака молочной железы у молодых пациенток (эндокринной терапии) на сайте МедикалПланет

В статьях данного раздела сайта использованы следующие сокращения:

  • АДФ — аденозиндифосфат
  • АИХ — аменорея, индуцированная химиотерапией
  • ГнРГ — гонадотропин-рилизинг гормон
  • ГР — гомологичная рекомбинация
  • ДИ — доверительный интервал
  • ДНК — дезоксирибонуклеиновая кислота
  • ИА — ингибиторы ароматазы
  • ИМТ — индекс массы тела
  • иРМЖ — ипсилатеральный рак молочной железы
  • кРМЖ — контралатеральный рак молочной железы
  • КСЯ — контролируемая стимуляция яичников
  • мРНК — матричная рибонуклеиновая кислота
  • МРР — местно-регионарный рецидив
  • МРТ — магнитно-резонансная томография
  • ОР — относительный риск
  • ОСО — органосохраняющая операция
  • ПК — протоковая карцинома
  • ПМЛТ — постмастэктомическая лучевая терапия
  • ПНЯ — преждевременная недостаточность яичников
  • пПО — полный патоморфологический ответ
  • ПФЯ — подавление функций яичников
  • РМЖ — рак молочной железы
  • РНК — рибонуклеиновая кислота
  • тнРМЖ — тройной негативный рак молочной железы
  • УЗИ — ультразвуковое исследование ЭТ — эндокринная терапия
  • ADM (от англ, acellular dermal matrix) — бесклеточная кожная матрица
  • DRFI (от англ, distant recurrence-free interval) — выживаемость без отдаленных рецидивов
  • EORTC (от англ. European Organization for Research and Treatment of Cancer) — Европейская организация по исследованию и лечению рака
  • ER (от англ, estrogen receptor) — рецептор эстрогена
  • ESMO (от англ. European Society for Medical Oncology) — Европейское общество медицинской онкологии
  • HER (от англ, human epidermal growth factor receptor) — рецептор эпидермального фактора роста
  • IBCSG (от англ. International Breast Cancer Study Group) - Международная группа по изучению рака молочной железы
  • LD (от лат. latissimus dorsi) — широчайшая мышца спины
  • NCCN (от англ. National Comprehensive Cancer Network) — Национальная комплексная онкологическая сеть
  • РАМ50 (от англ, prediction analysis of the microarrays) — количественный анализ 50 генов с помощью полимеразной цепной реакции в режиме реального времени
  • PARP (от англ. poly-(ADP-ribose) polymerases) — поли-(АДФ-рибоза)-полимераза
  • PgR (от англ, progesterone receptor) — рецептор прогестерона
  • PI3K (от англ, phosphoinositide 3-kinase) — фосфоинозитид-3-киназа
  • ROR-PT (от англ, risk of recurrence score) — балл риска рецидива
  • SEER (от англ. Surveillance, Epidemiology, and End Results) — анализ течения, распространенности и исходов злокачественных новообразований

При подготовке статей по лечению гормонами раннего рака молочной железы у молодых пациенток (эндокринной терапии) на сайте МедикалПланет использованы труды исключительно признанных зарубежных авторов:

  1. Azim Н.А. Jr et al. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling // Clin. Cancer Res. 2012. Vol. 18, N5. P. 1341-1351.
  2. Keegan Т.Н. et al. Occurrence of breast cancer subtypes in adolescent and young adult women // Breast Cancer Res. 2012. Vol. 14, N 2. P. R55.
  3. Swain S.M. et al. Quantitative gene expression by recurrence score in ER-positive breast cancer, by age // Adv. Ther. 2015. Vol. 32, N 12. P. 1222-1236.
  4. Chollet-Hinton L. et al. Breast cancer biologic and etiologic heterogeneity by young age and menopausal status in the Carolina breast cancer study: a casecontrol study // Breast Cancer Res. 2016. Vol. 18, N 1. P. 79.
  5. Partridge A.H. et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival // J. Clin. Oncol. 2016. Vol. 34, N 27. P. 3308-3314.
  6. Sestak L, Cuzick J. Markers for the identification of late breast cancer recurrence // Breast Cancer Res. 2015. Vol. 17. P. 10.
  7. Paik S. et al. A multigene assay to predict recurrence of tamoxifen-treated, nodenegative breast cancer // N. Engl. J. Med. 2004. Vol. 351, N 27. P. 2817-2826.
  8. Sparano J. A. et al. Prospective validation of a 21-gene expression assay in breast cancer // N. Engl. J. Med. 2015. Vol. 373, N 21. P. 2005-2014.
  9. Cardoso E et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer // N. Engl. J. Med. 2016. Vol. 375, N 8. P. 717-729.
  10. Paluch-Shimon S. et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) // Breast. 2017. Vol. 35. P. 203-217.
  11. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials // Lancet. 2011. Vol. 378, N 9793. P. 771-784.
  12. Burstein HJ. et al. Adjuvant endocrine therapy for women with hormone receptorpositive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression //J. Clin. Oncol. 2016. Vol. 34, N 14. P. 1689-1701.
  13. Curigliano G. et al. De-escalating and escalating treatments for early-stage breast cancer: the St Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 // Ann. Oncol. 2017. Vol. 28, N 8. P. 1700-1712.
  14. Senkus E. et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up // Ann. Oncol. 2015. Vol. 26, suppl. 5. P. v8-v30.
  15. Dowsett M. et al. The biology of steroid hormones and endocrine treatment of breast cancer // Breast. 2005. Vol. 14, N 6. P. 452-457.
  16. Francis PA. et al. Adjuvant ovarian suppression in premenopausal breast cancer// N. Engl. J. Med. 2015. Vol. 372, N 5. P. 436-446.
  17. Pagani O. et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer // N. Engl. J. Med. 2014. Vol. 371, N 2. P. 107-118.
  18. Regan М.М. et al. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials // Breast. 2013.Vol. 22, N 6. P. 1094-1100.
  19. Regan M.M. et al. Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials //J. Clin. Oncol. 2016. Vol. 34, N 19. P. 2221-2231.
  20. Zhou Q. et al. Prognostic impact of chemotherapy-induced amenorrhea on premenopausal breast cancer: a meta-analysis of the literature // Menopause. 2015.Vol. 22, N 10. P. 1091-1097.
  21. Francis PA. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer // N. Engl. J. Med. 2018. Vol. 379, N 2. P. 122-137.
  22. Tevaarwerk A.J. et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the eastern cooperative oncology group //J. Clin. Oncol. 2014. Vol. 32, N 35. P. 3948-3958.
  23. Sparano J.A. et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer // N. Engl. J. Med. 2018. Vol. 379, N 2. P. 111-121.
  24. Francis PA. Adjuvant endocrine therapy for premenopausal women: type and duration // Breast. 2017. Vol. 34, suppl. 1. P. S108-S111.
  25. Rossi L., Pagani O. The role of gonadotropin-releasing-hormone analogues in the treatment of breast cancer //J. Womens Health (Larchmt.). 2018. Vol. 27, N 4. P. 466-475.
  26. Pagani O., Regan M.M., Francis PA. Are SOFT and TEXT results practice changing and how? // Breast. 2016. Vol. 27. P. 122-125.
  27. Lamerato L. et al. Breast cancer recurrence and related mortality in U.S. patients with early breast cancer //J. Clin. Oncol. 2005. Vol. 23, suppl. 16. P. 738.
  28. Le M.G. et al. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma // Cancer. 2002. Vol. 94, N 11. P. 2813-2820.
  29. Sorensen S.V et al. Incidence-based cost-of-illness model for metastatic breast cancer in the United States // Int. J. Technol. Assess. Health Care. 2012. Vol. 28, N 1. P. 12-21.
  30. Gnant M. et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12 // Ann. Oncol. 2015. Vol. 26, N 2. P. 313-320.
  31. Saha P. et al. Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials //J. Clin. Oncol. 2017. Vol. 35, N 27. P. 3113-3122.
  32. Regan M.M. et al. Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT // Ann. Oncol. 2017. Vol. 28, N 9. P. 2225-2232.
  33. Lambertini M. et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data //J. Clin. Oncol. 2018. Vol. 36, N 19. P. 1981-1990.
  34. Pfeiler G. et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial //J. Clin. Oncol. 2011. Vol. 29, N 19. P. 2653-2659.
  35. Jatoi I. et al. Breast cancer adjuvant therapy: time to consider its time-dependent effects //J. Clin. Oncol. 2011'. Vol. 29, N 17. P. 2301-2304.
  36. Yu K.D. et al. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy // J. Clin. Endocrinol. Metab. 2012. Vol. 97, N 12. P. E2201-E2209.
  37. Wimmer K. et al. Optimal duration of adjuvant endocrine therapy: how to apply the newest data // Ther. Adv. Med. Oncol. 2017. Vol. 9, N 11. P. 679-692.
  38. Davies C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial // Lancet. 2013. Vol. 381, N 9869. P. 805-816.
  39. Goss PE. et al. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-control led NCIC CTG MA17 trial of extended adjuvant letrozole // Ann. Oncol. 2013. Vol. 24, N 2. P. 355-361.
  40. Ruddy KJ. et al. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen // Clin. Breast Cancer. 2014.Vol. 14, N6. P. 413-416.
  41. Noh W.C. et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study //J. Clin. Oncol. 2018. Vol. 36, suppl. 15. P. 502.
  42. Runowicz C.D. et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline // J. Clin. Oncol. 2016. Vol. 34, N6. P. 611-635.
  43. Rosenberg S.M. et al. Symptoms and symptom attribution among women on endocrine therapy for breast cancer // Oncologist. 2015. Vol. 20, N 6. P. 598-604.
  44. Takeuchi E.E. et al. Impact of patient-reported outcomes in oncology: a longitudinal analysis of patient-physician communication // J. Clin. Oncol. 2011.Vol. 29, N 21. P. 2910-2917.
  45. Chen J., Ou L., Hollis S.J. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting // BMC Health Serv. Res. 2013. Vol. 13. P. 211.
  46. Absolom K. et al. Electronic patient self-reporting of adverse-events: patient information and aDvice (eRAPID): a randomised controlled trial in systemic cancer treatment // BMC Cancer. 2017. Vol. 17, N 1. P. 318.
  47. Holch P. et al. Development of an integrated electronic platform for patient selfreport and management of adverse events during cancer treatment // Ann. Oncol. 2017. Vol. 28, N 9. P. 2305-2311.
  48. Henry N.L. Endocrine therapy toxicity: management options // Am. Soc. Clin. Oncol. Educ. Book. 2014. Vol. 34. P. e25-e30.
  49. Sverrisdottir A. et al. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy // J. Clin. Oncol. 2004. Vol. 22, N 18. P. 3694-3699.
  50. Vehmanen L. et al. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status //J. Clin. Oncol. 2006. Vol. 24, N 4. P. 675-680.
  51. Rossi L., Pagani O. The modern landscape of endocrine therapy for premenopausal women with breast cancer // Breast Care (Basel). 2015. Vol. 10, N 5. P. 312-315.
  52. Chien AJ. et al. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer // Breast Cancer Res. Treat. 2015. Vol. 153, N 1. P. 173-181.
  53. Braems G. et al. Use of tamoxifen before and during pregnancy // Oncologist. 2011. Vol. 16, N 11. P. 1547-1551.
  54. Christinat A., Di Lascio S., Pagani O. Hormonal therapies in young breast cancer patients: when, what and for how long? //J. Thorac. Dis. 2013. Vol. 5, suppl. 1. P. S36-S46.
  55. Paganini-Hill A., Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen // Breast Cancer Res. Treat. 2000. Vol. 64, N2. P. 165-176.
  56. Schilder C.M. et al. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial //J. Clin. Oncol. 2010. Vol. 28, N 8. P. 1294-1300.
  57. Nystedt M. et al. Side effects of adjuvant endocrine treatment in premenopausal breast cancer patients: a prospective randomized study //J. Clin. Oncol. 2003. Vol. 21, N9. P. 1836-1844.
  58. Phillips K.A. et al. Adjuvant ovarian function suppression and cognitive function in women with breast cancer // Br. J. Cancer. 2016. Vol. 114, N 9. P. 956-964.
  59. Underwood E.A. et al. Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis // Breast Cancer Res. Treat. 2018. Vol. 168, N 2. P. 299-310.
  60. Kelly C.M., Pritchard K.I. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned //J. Natl Cancer Inst. 2012. Vol. 104, N 6. P. 427-428.
  61. Sacco K., Grech G. Actionable pharmacogenetic markers for prediction and prognosis in breast cancer // EPMA J. 2015. Vol. 6, N 1. P. 15.
  62. Ribi K. et al. Adjuvant Tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial //J. Clin. Oncol. 2016.Vol. 34, N 14. P. 1601-1610.
  63. Hurny C. et al. The Perceived Adjustment to Chronic Illness Scale (PACIS): a global indicator of coping for operable breast cancer patients in clinical trials. Swiss Group for Clinical Cancer Research (SAKK) and the International Breast Cancer Study Group (IBCSG) // Support. Care Cancer. 1993. Vol. 1, N 4. P. 200-208.
  64. Dowsett M., Folkerd E. Deficits in plasma oestradiol measurement in studies and management of breast cancer // Breast Cancer Res. 2005. Vol. 7, N 1. P. 1-4.
  65. Bellet М. et al. Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant Triptorelin plus Exemestane or Tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy //J. Clin. Oncol. 2016. Vol. 34, N 14. P. 1584-1593.
  66. Masuda N. et al. Monthly versus 3-monthly goserelin acetate treatment in premenopausal patients with estrogen receptor-positive early breast cancer // Breast Cancer Res. Treat. 2011. Vol. 126, N 2. P. 443-451.
  67. Bernhard J. et al. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials // Lancet Oncol. 2015. Vol. 16, N 7. P. 848-858.
  68. Artigalas O. et al. Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis // BMC Med. 2015. Vol. 13. P. 139.
  69. Johansson H. et al. Impact of CYP19A1 and ESRI variants on early-onset side effects during combined endocrine therapy in the TEXT trial // Breast Cancer Res. 2016. Vol. 18, N 1. P. 110.
  70. Pagani O. et al. Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93 // Breast Cancer Res. Treat. 2013. Vol. 142, N 2. P. 455-459.
  71. Hershman D.L et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer // Breast Cancer Res Treat. 2011. Vol. 126, N 2. P. 529-537.
  72. Murphy C.C. et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review // Breast Cancer Res. Treat. 2012.Vol. 134, N 2. P. 459-478.
  73. Llarena N.C. et al. Impact of fertility concerns on tamoxifen initiation and persistence // J. Natl Cancer Inst. 2015. Vol. 107, N 10. Article ID djv202.
  74. Cluze C. et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time // Ann. Oncol. 2012. Vol. 23, N 4. P. 882-890.
  75. Brufsky A.M., Dickler M.N. Estrogen receptor-positive breast cancer: exploiting signaling pathways implicated in endocrine resistance // Oncologist. 2018. Vol. 23. P. 528.

- Вернуться в оглавление раздела "Стоматология"

Редактор: Искандер Милевски. Дата публикации: 21.8.2026